Add the following:

Alprazolam Orally Disintegrating **Tablets**

DEFINITION

Alprazolam Orally Disintegrating Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of alprazolam $(C_{17}H_{13}CIN_4).$

IDENTIFICATION

• The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

ASSAY

PROCEDURE

Buffer: 6.8 g/L of monobasic potassium phosphate in water. Adjust with phosphoric acid to a pH of 3.5. Diluent: Ácetonitrile and water (60:40)

- Mobile phase: Acetonitrile, methanol, and Buffer (35:10:
- Standard solution: 10 µg/mL of USP Alprazolam RS in Diluent

Sample solution: 10 μ g/mL of alprazolam in *Diluent*. Prepare using 10 Tablets, and pass through a suitable filter. [NOTE—Sonicate with intermittent shaking to help dissolve, if necessary.]

Chromatographic system

```
(See Chromatography (621), System Suitability.)
Mode: LC
Detector: UV 221 nm
Column: 4.6-mm × 15-cm; 5-μm packing L7
Column temperature: 30°
```

Flow rate: 1.5 mL/min

Injection volume: 30 µL

- System suitability
- Sample: Standard solution Suitability requirements
- Tailing factor: NMT 1.5
- Relative standard deviation: NMT 2.0%
- Analysis

Samples: Standard solution and Sample solution Calculate the percentage of the labeled amount of alprazolam $(C_{17}H_{13}CIN_4)$ in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

- = peak response from the Sample solution r_U
- = peak response from the Standard solution rs
- = concentration of USP Alprazolam RS in the Ċs Standard solution (µg/mL)

Cu = nominal concentration of alprazolam in the Sample solution (µg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

Change to read:

DISINTEGRATION $\langle 701 \rangle$

- Test 1 (RB 1-May-2012) Time: NMT 60 s Test 2: If the product complies with this test, the labeling indicates that it meets USP Disintegration Test 2. Time: NMT 30 Se (RB 1-May-2012)

Alprazolam 1

Change to read:

- **DISSOLUTION** $\langle 711 \rangle$

Test 1• (RB 1-May-2012) **Medium:** pH 6.0 phosphate buffer ([®]8 g/L of monobasic potassium phosphate and 2 g/L of dibasic potassium phosphate in water. Adjust with phosphoric acid or diluted potassium hydroxide to a pH of 6.0 ± 0.1 • (RB 1-May-2012)); 900 mL Apparatus 2: 50 rpm

- Time: 10 min
- **Mobile phase, Chromatographic system,** and **System suitability:** Proceed as directed in the *Assay*, except use an injection size of 100 μL.
- Standard stock solution: 50 µg/mL of USP Alprazolam RS in methanol. [NOTE—Sonicate to help dissolve, if necessary.]
- **Standard solution:** $(L/1000) \mu g/mL$ of USP Alprazolam RS in *Medium* from the *Standard stock solution*, where L is the label claim in µg/Tablet

Sample solution: Pass a portion of the solution under test through a nylon membrane filter of 0.45-µm pore size, discarding the first few mL.

Analysis

V

Samples: Standard solution and Sample solution Calculate the percentage of the labeled amount of alprazolam ($C_{17}H_{13}CIN_4$) dissolved:

Result =
$$(r_U/r_s) \times C_s \times V \times (1/L) \times 100$$

- = peak response from the Sample solution r_U
- = peak response from the Standard solution rs
- = concentration of USP Alprazolam RS in the Cs
 - Standard solution (mg/mL)
 - = volume of *Medium*, 900 mL = label claim (mg/Tablet)

Tolerances: NLT 80% (*Q*) of the labeled amount of alprazolam ($C_{17}H_{13}CIN_4$) is dissolved.

- **Test 2:** If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.
- **Medium:** pH 6.0 phosphate buffer (8 g/L of monobasic potassium phosphate and 2 g/L of dibasic potassium phosphate in water, adjusted with phosphoric acid or potassium hydroxide to a pH of 6.0 ± 0.1); 500 mL Apparatus 2: 50 rpm
- Time: 10 min

Buffer: 1.36 g/L of monobasic potassium phosphate adjusted with dilute sodium hydroxide to a pH of 6.0 Mobile phase: Acetonitrile and *Buffer* (35:65)

- Standard stock solution: 50 µg/mL of USP Alprazolam RS in methanol. [NOTE—Sonicate to help dissolve, if necessary.
- **Standard solution:** (L/500) μg/mL of USP Alprazolam RS in *Medium* from the *Standard stock solution*, where L is the label claim in µg/Tablet

Sample solution: Pass a 5-mL aliquot of the solution under test through a suitable filter of 0.45-µm pore size, discarding the first 3 mL. Chromatographic system

(See Chromatography (621), System Suitability.) Mode: LC

Detector: UV 230 nm

Column: 4.6-mm \times 7.5-cm; 5- μ m packing L7

Flow rate: 1.5 mL/min Injection volume: 40 µL

Run time: 3 times the retention time of alprazolam

System Suitability

Sample: Standard solution Suitability requirements Tailing factor: NMT 2.0 Relative standard deviation: NMT 2.0%

Analysis

Samples: Standard solution and Sample solution Calculate the percentage of the labeled amount of alprazolam (C17H13CIN4) dissolved:

Result = $(r_U/r_s) \times C_s \times V \times (1/L) \times 100$

- = peak response from the Sample solution r
- = peak response from the *Standard solution* = concentration of USP Alprazolam RS in the r_s Cs Standard solution (mg/mL) = volume of Medium, 500 mL
- V
- L = label claim (mg/Tablet) **Tolerances:** NLT 70% (Q) of the labeled amount of alprazolam (C₁₇H₁₃ClN₄) is dissolved. (RB 1-May-2012) **UNIFORMITY OF DOSAGE UNITS** (905): Meet the
- requirements

IMPURITIES

• ORGANIC IMPURITIES

- Buffer and Diluent: Prepare as directed in the Assay. Solution A: Acetonitrile, methanol, and Buffer
- (25:20:55) Solution B: Acetonitrile, methanol, and Buffer (40:5:55) Mobile phase: See Table 1.

Time (min)	Solution A (%)	Solution B (%)
0	100	0
12	100	0
15	0	100
60	0	100
65	100	0
70	100	0

Standard solution: 0.6 µg/mL of USP Alprazolam RS in Diluent

Sample solution: 200 µg/mL of alprazolam in Diluent. Prepare using 10 Tablets, and pass through a suitable filter.

Chromatographic system

(See Chromatography (621), System Suitability.) Mode: LC Detector: UV 240 nm **Column:** 4.6-mm × 15-cm; 5-µm packing L7 **Column temperature:** 30° Flow rate: 1.2 mL/min Injection volume: 25 µL System suitability Sample: Standard solution Suitability requirements Theoretical plates: NLT 2000 Tailing factor: NMT 1.5 Relative standard deviation: NMT 6.0% Analysis Samples: Standard solution and Sample solution Calculate the percentage of each impurity in the portion

of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

- r_U = peak response of each impurity from the Sample solution
- rs = peak response of alprazolam from the Standard solution
- = concentration of USP Alprazolam RS in the Cs Standard solution (µg/mL)
- = nominal concentration of alprazolam in the Cu Sample solution (µg/mL) = relative response factor (see Table 2) F

Acceptance criteria: See Table 2. Disregard any peaks less than 0.05%.

Table 2	2
---------	---

Tuble 2				
Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria, NMT (%)	
Alprazolam related compound A ^{a,b}	0.8	—	—	
Alprazolam	1.0	_	_	
2-Amino-5- chlorobenzophenone	2.9	1.9	0.5	
Any other unknown impurity	—	1.0	0.5	
Total impurities	_	_	2.0	

^a 2-(2-Acetylhydrazino)-7-chloro-5-phenyl-3H-1,4-benzodiazepine.

^b Disregard the peak due to alprazolam related compound A, because it is a process impurity in alprazolam.

ADDITIONAL REQUIREMENTS

• PACKAGING AND STORAGE: Preserve in tight containers, and store at controlled room temperature.

Add the following:

• **LABELING:** When more than one *Disintegration* test is given, the labeling states the *Disintegration* test used only if *Test 1* is not used. When more than one *Dissolution* test is given, the labeling states the Dissolution test used only if Test 1 is not used. (RB 1-May-2012)

USP REFERENCE STANDARDS $\langle 11 \rangle$

USP Alprazolam RS USP35